Drug Approval | June 24, 2022
Rivaroxaban approved in Japan for patients with PAD after revascularisation
It´s the first trial to demonstrate the benefits of dual pathway inhibition
It´s the first trial to demonstrate the benefits of dual pathway inhibition
ArisGlobal acquires Boehringer Ingelheim’s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector
The Indian Pharmacopoeia Commission (IPC) has added 23 new impurities standards and 7 new Indian Pharmacopoeial Reference standards
TCS provides clinical research services such as clinical data management, regulatory affairs, pharmacovigilance, risk-based monitoring, biostatistics and programming, medical writing, medical affairs and medico marketing, and health economics and outcomes research
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
Subscribe To Our Newsletter & Stay Updated
